{"meshTags":["Mutation","GTP Phosphohydrolases","Melanoma","Proto-Oncogene Proteins B-raf","Enzyme Inhibitors","Antineoplastic Combined Chemotherapy Protocols","Membrane Proteins","Antineoplastic Agents","Clinical Trials as Topic","Humans","Leukemia"],"meshMinor":["Mutation","GTP Phosphohydrolases","Melanoma","Proto-Oncogene Proteins B-raf","Enzyme Inhibitors","Antineoplastic Combined Chemotherapy Protocols","Membrane Proteins","Antineoplastic Agents","Clinical Trials as Topic","Humans","Leukemia"],"genes":["mitogen-activated protein kinase","BRAF(V600) proteins","BRAF","MEK"],"organisms":["9606"],"publicationTypes":["Journal Article"],"abstract":"Paradoxical activation of the mitogen-activated protein kinase pathway can cause secondary malignancies in patients treated with inhibitors of BRAF(V600) proteins. Characterization of a patient with concurrent BRAF-mutant melanoma and NRAS-mutant leukemia treated intermittently with combined BRAF and MEK inhibition provides new insights into the potential clinical and molecular effects of this therapeutic strategy.","title":"Finding the right balance of BRAF inhibition in melanoma.","pubmedId":"24795008"}